Everything below concerns peptide fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-23. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
== History == NCYC were founded in 1948 when a group of British brewers, who later formed the Brewing Industry Research Foundation, decided to store their yeast cultures in a single, safe deposit to ensure their longevity. In 1981 NCYC evolved into a broader collection when it moved to Institute of Food Research. in Norwich, in which it collected food spoilage yeast which was able to evade the conventional food preservatives. In 1999, the collection became a part of The United Kingdom National Culture Collection (UKNCC)., which was established to co-ordinate the activities of Britain’s national collections of microbial organisms. In 2019, the collection moved to the new facility in Quadram Institute Biosciences in the Norwich Research Park where it is currently based. NCYC trades under QIB Extra Ltd, a wholly owned commercial subsidiary of the Quadram Institute Bioscience, based at the Quadram Institute that specialises in bespoke research services for the food, health and allied industries.
Clocks, watches, and instruments dating from the first half of the 20th century, often in military applications, may have been painted with radioactive luminous paint. They are usually no longer luminous; this is not due to radioactive decay of the radium (which has a half-life of 1600 years) but to the fluorescence of the zinc sulfide fluorescent medium being worn out by the radiation from the radium. Originally appearing as white, most radium paint from before the 1960s has tarnished to yellow over time. The radiation dose from an intact device is usually only a hazard when many devices are grouped together or if the device is disassembled or tampered with.
== Medical uses == Stimulants are widely used throughout the world as prescription medicines as well as without a prescription (either legally or illicitly) as performance-enhancing or recreational drugs. Stimulants produce a noticeable crash or comedown at the end of their effects. In the US, the most frequently prescribed stimulants as of 2013 were lisdexamfetamine (Vyvanse), methylphenidate (Ritalin), and amphetamine (Adderall). It was estimated in 2015 that the percentage of the world population that had used cocaine during a year was 0.4%. For the category "amphetamines and prescription stimulants" (with "amphetamines" including amphetamine and methamphetamine) the value was 0.7%, and for MDMA 0.4%. Stimulants have been used in medicine for many conditions including obesity, sleep disorders, mood disorders, impulse-control disorders, asthma, nasal congestion and, in case of cocaine, as local anesthetics. Drugs used to treat obesity are called anorectics and generally include drugs that follow the general definition of a stimulant, but other drugs such as cannabinoid receptor antagonists also belong to this group. Eugeroics are used in management of sleep disorders characterized by excessive daytime sleepiness, such as narcolepsy, and include stimulants such as modafinil and pitolisant. Stimulants are used in impulse control disorders such as ADHD and off-label in mood disorders such as major depressive disorder to increase energy, focus, and elevate mood.
His first play NotMoses opened in London's West End; wrote, directed and produced a psychological thriller The Unseen; has also written for The Jewish Chronicle, Jewish News, Times of Israel and The Guardian. Gillian Slovo (born 15 March 1952); South African Jewish playwright, novelist and author who lives in the UK; recipient of Golden PEN Award; moved to London in 1964, as political exile. Her family is Jewish. Tom Stoppard (born Tomáš Sträussler, 3 July 1937); playwright, screenwriter; has written for film, radio, stage, and television, finding prominence with plays; work covers themes of human rights, censorship, and political freedom, philosophical thematics of society; has been a playwright of National Theatre and is one of the most internationally performed dramatists of his generation; was knighted for his contribution to theatre by Queen Elizabeth II. Alfred Sutro, OBE (7 August 1863 – 11 September 1933) was an English dramatist, writer and translator. In addition to a succession of successful plays of his own in the first quarter of the 20th century, Sutro made the first English translations of works by the Belgian writer Maurice Maeterlinck. Jackie Walker (activist), anti Zionist anti fascist playwright and pro Palestinian author of Sephardi Jewish and Jamaican origin. Arnold Wesker, playwright, FRSL (24 May 1932 – 12 April 2016) was an English dramatist. He was the author of 50 plays, four volumes of short stories, two volumes of essays, much journalism and a book on the subject, a children's book, some poetry, and other assorted writings.
== Signs and symptoms == Buried bumper syndrome may be asymptomatic, especially early in the course. Dysfunction of the tube occurs commonly, including leakage around the insertion site, inability to administer feedings or fluids, or need for more pressure when giving feeds. Buried bumper syndrome may cause abdominal pain or swelling (erythema) at the site of insertion of the PEG tube. Less commonly, buried bumper syndrome may also be complicated by acute infectious illness (sepsis), abscess formation, gastrointestinal bleeding or peritonitis. In some cases, the internal bumper may be felt by palpating the abdomen. Inspection of the tube typically reveals an inability to easily rotate the tube.
Sources: en.wikipedia.org
Version 1.4a was published in February 2015; the underlying DisplayPort version was updated to 1.3 in order to support HBR3 data rates, Display Stream Compression 1.1, Segmented Panel Displays, and partial updates for Panel Self-Refresh. Version 1.4b was published in October 2015; its protocol refinements and clarifications are intended to enable adoption of eDP 1.4b in devices by mid-2016. Version 1.5 was published in October 2021; adds new features and protocols, including enhanced support for Adaptive-Sync, that provide additional power savings and improved gaming and media playback performance.
The publishing of this list and the subsequent fall-out, banks indiscriminately de-risking MSBs, is referred to as Operation Choke Point. The Financial Crimes Enforcement Network issued a Geographic Targeting Order to combat illegal money laundering in the United States. This means that title insurance companies in the U.S. are required to identify the natural persons behind companies that pay all cash in residential real estate purchases over a particular amount in certain U.S. cities. The Corporate Transparency Act (CTA) is a significant piece of legislation in the United States aimed at combating money laundering and enhancing financial transparency. Enacted as part of the National Defense Authorization Act for Fiscal Year 2021, the CTA mandates that corporations, limited liability companies (LLCs), and similar entities disclose information about their beneficial owners to the Financial Crimes Enforcement Network (FinCEN). This requirement is designed to help authorities identify and track individuals who control or profit from these entities, thereby closing loopholes often exploited for illicit activities. The CTA requires entities to file Beneficial Ownership Information (BOI) reports with FinCEN. These reports must include details such as the names, addresses, dates of birth, and identification numbers of the beneficial owners. By gathering this information, the CTA aims to create a comprehensive database that federal, state, and local law enforcement agencies can access to investigate and prevent financial crimes.
=== Toxicity === In 2009, one case of sympathomimetic toxicity was reported in the UK after a person took 0.2 g of mephedrone orally, and after this did not achieve the desired effect, intramuscularly injected 3.8 g mixed with water into his thighs. Shortly afterwards, the user "developed palpitations, blurred tunnel vision, chest pressure and sweating". The patient was treated with 1 mg of lorazepam and the sympathomimetic features decreased and the user was discharged within six hours of arrival. One case of serotonin syndrome has been reported, where the patient was already prescribed fluoxetine and olanzapine, and then took 40 tablets containing mephedrone in one night. He was treated with lorazepam and discharged 15 hours after admission. Both enantiomers of methcathinone, which differs only in the lack of the methyl group on the phenyl ring when compared to mephedrone, have been shown to be toxic to rat dopamine neurons, and the S-enantiomer was also toxic against serotonin neurons. Simon Gibbons and Mire Zloh of the School of Pharmacy, University of London stated, based on the chemical similarities between methcathinone and mephedrone, "it is highly likely that mephedrone will display neurotoxicity". However, Brunt and colleagues stated, "extreme caution" should be used when inferring the toxicity of mephedrone from methcathinone, noting some of the toxicity associated with methcathinone is due to manganese impurities related to its synthesis, rather than the compound itself.
CH3OH + HCl → CH3Cl + H2O A smaller amount of chloromethane is produced by treating a mixture of methane with chlorine at elevated temperatures. This method, however, also produces more highly chlorinated compounds such as dichloromethane, chloroform, and carbon tetrachloride. For this reason, methane chlorination is usually only practiced when these other products are also desired. This chlorination method also cogenerates hydrogen chloride, which poses a disposal problem.
Acids are fundamental reagents in treating almost all processes in modern industry. Sulfuric acid, a diprotic acid, is the most widely used acid in industry, and is also the most-produced industrial chemical in the world. It is mainly used in producing fertilizer, detergent, batteries and dyes, as well as used in processing many products such like removing impurities. According to the statistics data in 2011, the annual production of sulfuric acid was around 200 million tonnes in the world. For example, phosphate minerals react with sulfuric acid to produce phosphoric acid for the production of phosphate fertilizers, and zinc is produced by dissolving zinc oxide into sulfuric acid, purifying the solution and electrowinning. In the chemical industry, acids react in neutralization reactions to produce salts. For example, nitric acid reacts with ammonia to produce ammonium nitrate, a fertilizer. Additionally, carboxylic acids can be esterified with alcohols, to produce esters. Acids are often used to remove rust and other corrosion from metals in a process known as pickling. They may be used as an electrolyte in a wet cell battery, such as sulfuric acid in a car battery.
Sources: en.wikipedia.org
Many drugs are metabolised by a set of liver enzymes called CYP450s. The activity of these enzymes would determine the rate of pro-drug activation and the rate of inactivation of active drugs. For example, warfarin, a commonly used anticoagulant drug in atrial fibrillation, is metabolised by an enzyme called CYP2C9. Phenytoin, a CYP2C9 inducer, would increase its activity and the rate of warfarin breakdown, thereby reducing its efficacy. Patients should avoid the co-administration of warfarin and phenytoin. In cases where both drugs must be used together, warfarin dosing may be titrated up to cope with the reduced efficacy. The kidney excretes most drugs through urine. Since urine is weakly alkaline in nature, weakly acid drugs would ionise in urine, making it difficult for them to be reabsorbed. Therefore, in cases of aspirin (weak acid) toxicity, injecting intravenous sodium bicarbonate could increase urine pH, thereby increasing the excretion of aspirin through urine. A similar approach can be used in other weakly acidic drug toxicity.
=== Brand names === It was introduced under the brand names Quitaxon and Aponal by Boehringer and as Sinequan by Pfizer. Doxepin is marketed under many brand names worldwide, including: Adnor, Anten, Antidoxe, Colian, Deptran, Dofu, Doneurin, Dospin, Doxal, Doxepini, Doxesom, Doxiderm, Flake, Gilex, Ichderm, Li Ke Ning, Mareen, Noctaderm, Oxpin, Patoderm, Prudoxin, Qualiquan, Quitaxon, Sagalon, Silenor, Sinepin, Sinequan, Sinquan, and Zonalon. It is also marketed as a combination drug with levomenthol under the brand name Doxure.
In biotechnology, polymersomes are a class of artificial vesicles, tiny hollow spheres that enclose a solution. Polymersomes are made using amphiphilic synthetic block copolymers to form the vesicle membrane, and have radii ranging from 50 nm to 5 μm or more. Most reported polymersomes contain an aqueous solution in their core and are useful for encapsulating and protecting sensitive molecules, such as drugs, enzymes, other proteins and peptides, and DNA and RNA fragments. The polymersome membrane provides a physical barrier that isolates the encapsulated material from external materials, such as those found in biological systems. Synthosomes are polymersomes engineered to contain channels (transmembrane proteins) that allow certain chemicals to pass through the membrane, into or out of the vesicle. This allows for the collection or enzymatic modification of these substances. The term "polymersome" for vesicles made from block copolymers was coined in 1999. Polymersomes are similar to liposomes, which are vesicles formed from naturally occurring lipids. While having many of the properties of natural liposomes, polymersomes exhibit increased stability and reduced permeability. Furthermore, the use of synthetic polymers enables designers to manipulate the characteristics of the membrane and thus control permeability, release rates, stability and other properties of the polymersome.
== Use and effects == While 2C-EF was briefly mentioned by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), its properties and effects were not described. Subsequently, in his book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, Shulgin listed 2C-EF's dose range as 6 to 12 mg orally and its duration as 12 hours. This information was cited via personal communication with M. Mueller in 2006.
These samples bore similar superficial characteristics to P. cubensis, as well as similar habit and habitat. Microscopic and genetic testing of these samples led to the conclusion that they were closely related but different species, estimated to have shared a common ancestor some time in the last 3 million years. The new species bears the provisional name Psilocybe ochraceocentrata.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.